Eli Lilly and Company (LLY) Stock Forecast & Price Target

$1,177.57 +7.97 (+0.68%)

Closing price 10/9/2026 03:59 PM Eastern

Extended Trading

$1,177.40 -0.17 (-0.01%)

As of 10/9/2026 07:59 PM Eastern

Compare

Eli Lilly and Company - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Moderate Buy

Based on 30 Analyst Ratings

Sell
1

Hold
3

Buy
26

Based on 30 Wall Street analysts who have issued ratings for Eli Lilly and Company in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 30 analysts, 1 has given a sell rating, 3 have given a hold rating, 25 have given a buy rating, and 1 has given a strong buy rating for LLY.

Consensus Price Target

$1,313.43
11.54% Upside

According to the 30 analysts' twelve-month price targets for Eli Lilly and Company, the average price target is $1,313.43. The highest price target for LLY is $1,600.00, while the lowest price target for LLY is $900.00. The average price target represents a forecasted upside of 11.54% from the current price of $1,177.57.

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Get the Latest News and Ratings for LLY and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Eli Lilly and Company and its competitors.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

LLY Analyst Ratings Over Time

Type	Current Forecast 10/11/25 to 10/11/26	1 Month Ago 9/11/25 to 9/11/26	3 Months Ago 7/13/25 to 7/13/26	1 Year Ago 10/11/24 to 10/11/25
Strong Buy	1 Strong Buy rating(s)	1 Strong Buy rating(s)	2 Strong Buy rating(s)	1 Strong Buy rating(s)
Buy	25 Buy rating(s)	24 Buy rating(s)	23 Buy rating(s)	14 Buy rating(s)
Hold	3 Hold rating(s)	4 Hold rating(s)	4 Hold rating(s)	7 Hold rating(s)
Sell	1 Sell rating(s)	1 Sell rating(s)	1 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$1,313.43	$1,295.39	$1,266.74	$948.06
Forecasted Upside	11.54% Upside	16.12% Upside	6.83% Upside	13.80% Upside
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy	Moderate Buy

LLY Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

LLY Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Eli Lilly and Company Stock vs. The Competition

Type	Eli Lilly and Company	Healthcare Companies	Broader Market
Consensus Rating Score	2.87	2.32	2.53
Consensus Rating	Moderate Buy	Hold	Moderate Buy
Predicted Upside	11.54% Upside	927.85% Upside	19.60% Upside
News Sentiment Rating	Positive News See Recent LLY News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Show

Rating

Upside/Downside

Action

Report Date

0 Results

Export

Date	Brokerage	Analyst	Action	Rating	Price Target	Report Date Upside/Downside
10/8/2026	Cantor Fitzgerald 5 of 5 stars	Carter Gould 4 of 5 stars	Boost Target	Overweight	$1,410.00 ➝ $1,440.00	+21.32%
10/7/2026	Morgan Stanley 3 of 5 stars	Terence Flynn 5 of 5 stars	Boost Target	Overweight	$1,419.00 ➝ $1,430.00	+20.99%
10/1/2026	BMO Capital Markets 3 of 5 stars	Evan David Seigerman 3 of 5 stars	Reiterated Rating	Outperform
9/28/2026	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Chris Schott Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Overweight	$1,400.00 ➝ $1,500.00	+26.65%
9/22/2026	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Steve Scala Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Buy	$1,250.00	+7.24%
9/18/2026	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Seamus Fernandez Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Buy	$1,273.00 ➝ $1,284.00	+11.45%
9/17/2026	The Goldman Sachs Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Boost Target	Buy	$1,367.00 ➝ $1,371.00	+18.84%
9/15/2026	Berenberg Bank Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Kerry Holford Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Set Target	Hold ➝ Buy	$1,400.00	+22.92%
9/10/2026	HSBC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Rajesh Kumar Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Reduce	$850.00 ➝ $940.00	-16.33%
8/26/2026	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Upgrade	Buy (B-) ➝ Buy (B)
Get the Latest News and Ratings for LLY and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Eli Lilly and Company and its competitors with MarketBeat's FREE daily newsletter.
8/7/2026	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Michael Yee Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Set Target		$1,376.00	+16.86%
8/7/2026	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Robyn Karnauskas Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Buy	$1,370.00 ➝ $1,376.00	+16.57%
8/6/2026	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Mohit Bansal Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Overweight	$1,280.00 ➝ $1,330.00	+13.65%
7/15/2026	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Geoff Meacham Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Buy	$1,500.00 ➝ $1,600.00	+38.62%
7/14/2026	Sanford C. Bernstein Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Courtney Breen Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Outperform	$1,300.00 ➝ $1,385.00	+20.98%
7/10/2026	Bank of America Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Jason Gerberry Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Buy	$1,251.00 ➝ $1,334.00	+12.69%
7/8/2026	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Trung Huynh Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Outperform	$1,250.00 ➝ $1,500.00	+23.00%
6/25/2026	Leerink Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	David Risinger Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Outperform	$1,119.00 ➝ $1,232.00	+10.40%
6/9/2026	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Akash Tewari Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Buy	$1,330.00 ➝ $1,350.00	+18.19%
5/21/2026	Wolfe Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Alexandria Hammond Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Outperform	$1,350.00	+30.12%
5/7/2026	Rothschild & Co Redburn Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Boost Target		$880.00 ➝ $900.00	-7.27%
5/4/2026	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Emily Field Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Overweight	$1,350.00 ➝ $1,400.00	+44.62%
3/6/2026	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	James Shin Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Buy	$1,285.00	+30.49%
2/18/2026	Daiwa Securities Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Narumi Nakagiri Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Buy	$1,230.00 ➝ $1,250.00	+22.24%
2/11/2026	CICC Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Boost Target	Neutral	$1,060.00 ➝ $1,107.00	+5.53%
2/10/2026	Loop Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Ilya Zubkov Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Set Target		$1,200.00	+17.07%
2/10/2026	Freedom Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Upgrade	Hold ➝ Strong-Buy
2/9/2026	Argus Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Boost Target	Buy	$930.00 ➝ $1,200.00	+14.40%
2/5/2026	Scotiabank Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Reiterated Rating	Outperform	$1,300.00	+26.01%
1/30/2026	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Downgrade	Strong-Buy ➝ Hold
12/1/2025	National Bank Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Tim Anderson Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Set Target		$1,286.00	+21.58%
10/14/2025	Erste Group Bank Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Upgrade	Hold ➝ Buy
8/14/2025	DZ Bank Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Upgrade	Hold ➝ Strong-Buy

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Sunday at 04:37 AM ET.

Should I Buy Eli Lilly and Company Stock? LLY Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Tuesday, October 6, 2026. Please send any questions or comments about these Eli Lilly and Company pros and cons to contact@marketbeat.com.

Eli Lilly and Company
Bull Case

Here are some ways that investors could benefit from investing in Eli Lilly and Co:

Eli Lilly and Co recently reported strong financial performance, with revenue of $22.97 billion for the quarter, significantly exceeding analyst expectations of $20.82 billion and representing a 47.7% year-over-year increase. This robust growth is supported by the company's ability to beat earnings estimates, reporting $8.38 per share compared to the consensus of $6.40, which demonstrates strong operational efficiency and demand for its products.
The company's oral GLP-1 candidate, Foundayo, has shown superior results compared to oral semaglutide 25 mg in adults with type 2 diabetes, delivering greater weight loss and better blood-sugar control. This competitive advantage in the metabolic health sector could extend Eli Lilly and Co's market leadership and provide a significant catalyst for future revenue growth as the drug progresses through later-stage studies.
Eli Lilly and Co is expanding its oncology portfolio with the FDA's expanded approval of Jaypirca for previously untreated chronic lymphocytic leukemia and small lymphocytic lymphoma patients. Additionally, the experimental cancer drug olomorasib received FDA orphan-drug designation for pancreatic cancer, which may provide development incentives and potential market exclusivity, reinforcing the company's strategy to diversify beyond GLP-1 medicines.
The stock currently trades at $1,157.61, which is below the consensus price target of $1,311.96 set by Wall Street analysts. With a consensus rating of "Moderate Buy" and recent price target increases from firms like Cantor Fitzgerald and Citigroup, there is potential for upside as the market continues to price in the company's growth trajectory and recent positive developments.
Eli Lilly and Co has strengthened its drug discovery capabilities by expanding its collaboration with Gate Bioscience in a potential agreement worth more than $870 million. This deal, along with making insitro-developed machine-learning models available through Lilly TuneLab, could improve future drug discovery efficiency and add longer-term pipeline value, supporting sustained innovation and competitive advantage.

Eli Lilly and Company
Bear Case

Investors should be bearish about investing in Eli Lilly and Co for these reasons:

The company's valuation is elevated, with a price-to-earnings ratio of 38.85, which is well above the broader market average. This high valuation reflects very high growth expectations, meaning that any slowdown in demand for key products like Zepbound or Mounjaro, or any pricing pressure, could lead to significant stock price corrections as there is limited room for error.
Recent insider selling activity indicates potential caution among company executives. For example, EVP Patrik Jonsson sold 6,500 shares at an average price of $1,175.10, and EVP Anat Hakim sold 5,000 shares at $1,190.00. While these sales were executed under pre-arranged trading plans, the aggregate insider selling of 13,500 shares worth $15,958,170 in the last three months may signal a lack of confidence in the current stock price or a desire to diversify personal holdings.
The company faces potential risks from regulatory delays or trial setbacks, which could impact the commercial viability of its pipeline. For instance, early-stage updates for the eltrekibart antibody and a new basal-insulin candidate indicate continued pipeline progress, but Phase 1 results do not yet establish commercial viability, leaving uncertainty about the long-term success of these new products.
Eli Lilly and Co's debt-to-equity ratio of 1.41 suggests a relatively high level of leverage compared to its equity. While the company has a current ratio of 1.35 and a quick ratio of 1.00, indicating adequate short-term liquidity, the higher debt levels could limit financial flexibility in the event of economic downturns or increased interest rates, potentially impacting future investment in research and development.
The stock's beta of 0.46 indicates lower volatility compared to the broader market, but this also means it may not provide the same level of upside potential during strong market rallies. For investors seeking high-growth, high-volatility opportunities, Eli Lilly and Co's relatively stable price action may be less appealing, especially given the current high valuation and the need for sustained growth to justify the premium.

LLY Forecast - Frequently Asked Questions

According to the research reports of 30 Wall Street equities research analysts, the average twelve-month stock price forecast for Eli Lilly and Company is $1,313.43, with a high forecast of $1,600.00 and a low forecast of $900.00.

30 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Eli Lilly and Company in the last year. There is currently 1 sell rating, 3 hold ratings, 25 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" LLY shares.

According to analysts, Eli Lilly and Company's stock has a predicted upside of 11.54% based on their 12-month stock forecasts.

Over the previous 90 days, Eli Lilly and Company's stock had 3 upgrades and 1 downgrade by analysts.

Eli Lilly and Company has been rated by research analysts at Berenberg Bank, BMO Capital Markets, Cantor Fitzgerald, Citigroup, Guggenheim, HSBC, JPMorgan Chase & Co., Morgan Stanley, Sanford C. Bernstein, TD Cowen, The Goldman Sachs Group, Truist Financial, UBS Group, Weiss Ratings, and Wells Fargo & Company in the past 90 days.

Analysts like Eli Lilly and Company more than other "healthcare" companies. The consensus rating for Eli Lilly and Company is Moderate Buy while the average consensus rating for "healthcare" companies is Hold. Learn more on how LLY compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Brokerages With Eli Lilly and Company Recommendations

MarketBeat monitors more than a dozen sources for Eli Lilly and Company analyst ratings, with the most recent rating issued on 10/8/2026.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Eli Lilly and Company (LLY) Stock Forecast & Price Target